-
www.ahrq.gov/sites/default/files/wysiwyg/research/findings/ta/topicrefinement/ced-appendix2-comments.xlsx
June 02, 2025 - CMS and investigators agree on collaboration opportunities to facilitate mechanisms of secondary data … development CMS and investigators agree on collaboration opportunities to facilitate mechanisms of secondary
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/pediatric-cancer-survivorship-protocol.pdf
June 01, 2020 - changes,
kidney failure, liver disease, osteopenia and osteoporosis, neurocognitive deficits, and
secondary … Setting(s) All GQs:
• All care settings applicable to US settings will be
eligible, including primary, secondary
-
digital.ahrq.gov/sites/default/files/docs/publication/r18hs017017-logan-final-report-2009.pdf
January 01, 2009 - Most quality reporting programs depend on data registries (or
equivalent local processes) where secondary … to do is to automatically extract data from a specialty electronic health record without
requiring secondary
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/quantitative-synthesis-expanded-methods_methods.pdf
March 01, 2013 - AFCAPS/TexCAPS 6,605 0.1 1.04 1.36 0.69 167* 1,000* 28
WOSCOPS 6,595 0.4 0.78 0.67 0.7 118 182 28
Secondary … secondary
outcomes
Specify whether outcomes were primary or secondary outcomes
in the original studies
-
www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/syphilis-infection-in-nonpregnant-adults-and-adolescents-june-2016
June 07, 2016 - Symptoms correspond to stages of infection including primary, secondary, early- and late-latent, and … western United States. 2 , 8 , 9 Men who have sex with men accounted for 61% of all primary and secondary … by Stage of Untreated Syphilis, % (Range) b
Specificity, %
(Range) b
Mixed
Primary
Secondary
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/alcohol-misuse-drug-therapy_research-protocol.pdf
January 27, 2012 - either
physical (e.g., liver damage from chronic drinking) or mental (e.g., depressive episodes
secondary … focused on harms) and 5 (focused on
subgroups), we will also include non-RCTs, open-label
trials, secondary … • For KQ 6, we will also include secondary analyses or
subgroup analyses from trials and prospective
-
hcup-us.ahrq.gov/reports/statbriefs/sb215-Red-Blood-Cell-Transfusions-Trends.jsp
December 01, 2016 - Secondary diagnoses are concomitant conditions that coexist at the time of admission or develop during … All-listed diagnoses include the principal diagnosis plus these additional secondary conditions. … into a single Procedure Class using all-listed procedures (i.e., the principal procedure and up to 14 secondary
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/instrumental-variable-methods_research.pdf
April 01, 2010 - confounding is possible, but not expected to be severe, IV may be more appropriately
used as a secondary … Here, one might consider using the IV in a secondary or
sensitivity analysis. … IV as a Secondary Analysis. … are entirely different
from conventional methods, IV analysis may be useful as a confirmatory or secondary
-
digital.ahrq.gov/sites/default/files/docs/citation/r21hs023963-schnall-final-report-2018.pdf
January 01, 2018 - 0.185 0.077 0.063 0.101 0.534
Weight loss or wasting -0.254 0.070 -0.004 0.081 -0.250 0.107 0.020
Secondary … Outcomes
Table 3 illustrates the findings from our secondary outcome measures. … Difference in Difference of Secondary Outcome Measures
Variable Estimate Standard Significance
Error … Significance, Implications)
Principal Findings
Outcomes
Overall Use of mVIP
Impact on Symptom Burden
Secondary
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-stone-prevention_disposition-comments.pdf
July 26, 2012 - Peer Reviewer
#1
Introduction On page 10, might include malabsorption as an important
secondary cause … The authors did evaluate secondary or intermediate outcomes
such as stone recurrence. … The authors did evaluate secondary or intermediate outcomes
such as stone recurrence. … A priori, we judged stone growth to be a
secondary efficacy outcome measure, and one
that deserves
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/pain-chronic_disposition-comments.pdf
September 01, 2011 - #3
Background Some of the data on prevalence and cost presented in the
background are based on secondary … technical brief (footnote #4) uses the direct quote,
“Physical therapy, focusing on active therapy with secondary … concern is the potential to
increase risk for falls, change in cognition, and altered mental status
secondary
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-urinary-retention_disposition-comments.pdf
September 15, 2014 - acontractile detrusor secondary to cauda equine or peripheral
nerve injury)
It is more appropriate … to use the term benign prostatic
obstruction (BPO) which is secondary to BPH, rather than BPH
to describe … Methods The concept of CUR secondary to detrusor underactivity (or
acontractile bladder, or hypocontractile
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/hemorrhage-postpartum_disposition-comments.pdf
April 28, 2015 - Moderate shock secondary to PPH occurs when 30-
35% of blood volume is lost and this occurs when 1800 … from
procoagulant drugs (i.e. tranexamic acid,
thrombomodulin, rFVIIA, etc) which are intended for
secondary … Peer reviewer #3 Results Page 24 Line 8 The term “secondary hysterectomy
disunion” is one which many
-
hcup-us.ahrq.gov/reports/methods/2015-04.pdf
January 01, 2015 - the first-listed (primary) payer,
whereas the MedPAR count includes discharges with Medicare as a secondary … diagnosis w mcc 3,486 3,345 -4.0
847 Chemotherapy w/o acute leukemia as secondary diagnosis w cc 26,431 … 24,565 -7.1
848
Chemotherapy w/o acute leukemia as secondary diagnosis w/o
cc/mcc 1,302 1,345 … system & connective
tissue w mcc 3,364 3,355 -0.3
429 846
Chemotherapy w/o acute leukemia as secondary … Use of Secondary Procedure Days in the AHRQ Quality Indicators, Version 3.1
Table 5.
-
effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/biorepositories-registries-guide-3rd-ed-addendum-white-paper.pdf
February 01, 2018 - contain provisions permitting investigators to obtain broad consent to the storage, maintenance,
or secondary … Although the 2017 Final Rule provides the option of broad consent for the storage, maintenance,
or secondary … well as the following
additional elements for any research involving the storage, maintenance, or secondary … Secondary Uses and
the Governance of De-Identified Data:
Lessons from the Human Genome Diversity
Panel
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-cholestorol-medications_disposition-comments.pdf
March 10, 2010 - combination therapy may be appropriate, such as
patients with elevated triglycerides who need to achieve secondary … III Guidelines specifically recognize the need to
treat beyond LDL-C by establishing non-HDL-C as a secondary … combination therapy may be appropriate,
such as patients with elevated triglycerides who need to achieve
secondary … point (last measurement in the first
treatment period before possible simvastatin titration) and the secondary
-
hcup-us.ahrq.gov/db/nation/nis/tools/stats/NIS_2005_SummaryStats_CORE_Weighted.PDF
January 01, 2005 - NEOPL W OTHER O.R.PROC 5396 0.01
409: RADIOTHERAPY 5003 0.01
410: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … W CC 60245 0.15
464: SIGNS & SYMPTOMS W/O CC 19693 0.05
465: AFTERCARE W HISTORY OF MALIGNANCY AS SECONDARY … DIAGNOSIS 2972 0.01
466: AFTERCARE W/O HISTORY OF MALIGNANCY AS SECONDARY DIAGNOSIS 26289 0.07
467 … & LIMB REATTACHMENT PROCEDURES OF UPPER EXTREMITY 36504 0.09
492: CHEMOTHERAPY W ACUTE LEUKEMIA AS SECONDARY … Percent
of
Total
98: Essential hypertension 73654 0.19
99: Hypertension with complications and secondary
-
hcup-us.ahrq.gov/db/nation/nrd/stats/MaskedStats_NRD_2022_Core_Weighted.PDF
January 01, 2022 - OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH
MCC
8,817 0.03%
837: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … SEC DX WITH CC OR HIGH DOSE CHEMOTHERAPY AGENT 9,074 0.03%
838: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … CHEMO W/ ACUTE LEUKEMIA AS SEC DX WITHOUT CC/MCC 5,981 0.02%
839: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS WITH MCC 17,248 0.05%
847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH … CC 68,195 0.21%
848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT CC/MCC 1,972
-
hcup-us.ahrq.gov/db/nation/kid/tools/stats/KID_2022_MaskedStats_Core.PDF
January 01, 2022 - OR WITH HIGH DOSE CHEMOTHERAPY AGENT
WITH MCC
1,975 0.07%
837: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … SEC DX WITH CC OR HIGH DOSE CHEMOTHERAPY
AGENT
3,051 0.10%
838: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … CHEMO W/ ACUTE LEUKEMIA AS SEC DX WITHOUT CC/MCC 1,827 0.06%
839: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS WITH MCC 3,515 0.12%
847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH … CC 17,658 0.59%
848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT
CC/MCC
513
-
hcup-us.ahrq.gov/db/nation/kid/tools/stats/KID_2022_MaskedStats_Core_Weighted.PDF
January 01, 2022 - OR WITH HIGH DOSE CHEMOTHERAPY AGENT
WITH MCC
2,696 0.05%
837: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … SEC DX WITH CC OR HIGH DOSE CHEMOTHERAPY
AGENT
4,170 0.07%
838: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … CHEMO W/ ACUTE LEUKEMIA AS SEC DX WITHOUT CC/MCC 2,485 0.04%
839: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS WITH MCC 4,801 0.08%
847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH … CC 24,072 0.43%
848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT
CC/MCC
702